Wall Street Has a Mixed Opinion on GoodRx Holdings (GDRX)

GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the Best Penny Stocks to Buy with the Highest Upside Potential. Wall Street has a mixed opinion on GoodRx Holdings, Inc. (NASDAQ:GDRX) since the company released its fiscal second quarter results on August 6, 2025.

The company posted a revenue of $203.07 million, up slightly by 1.23% year-over-year, but below the consensus by $2.64 million. The EPS of $0.04 stayed in line with the expectations. Management noted that the prescription transaction revenue fell 3% to $143.1 million, mainly due to a 14% drop in Monthly Active Consumers caused by retail pharmacy changes. Moreover, the subscription revenue decreased 7% to $20.5 million, linked to fewer subscription plans.

Since the release, Wall Street has had a mixed opinion. For instance, on August 18, Michael Cherny from Leerink Partners reiterated a Buy rating on the stock with a price target of $6. Later on the same day, Steven Valiquette from Mizuho Securities reiterated a Hold rating on the stock with a price target of $5. More recently, on September 25, Allen Lutz from Bank of America Securities reiterated a Sell rating on $3.4 price target.

GoodRx Holdings, Inc. (NASDAQ:GDRX) is a US platform that helps consumers save money on medications.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.